Deutsche Bank AG Has $1.12 Million Stock Holdings in Sana Biotechnology, Inc. $SANA

Key Points

• Deutsche Bank AG has significantly increased its holdings in Sana Biotechnology by 87.9% during Q1, now owning approximately 0.30% of the company's stock valued at $1.12 million.
• Analysts are optimistic about Sana Biotechnology, with a consensus rating of "Buy" and a target price averaging around $8.00, despite the stock's recent performance.
• The company's stock price is currently at $3.58, having a 52-week range between $1.26 and $7.30, and a market capitalization of $851.36 million.

Deutsche Bank AG increased its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 87.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 666,392 shares of the company's stock after acquiring an additional 311,692 shares during the period. Deutsche Bank AG owned about 0.30% of Sana Biotechnology worth $1,120,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in SANA. Cerity Partners LLC acquired a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC boosted its position in shares of Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after acquiring an additional 10,548 shares in the last quarter. Syon Capital LLC acquired a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $27,000. Ameriprise Financial Inc. acquired a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $29,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Sana Biotechnology during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $8.00.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.58 on Friday. Sana Biotechnology, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The firm has a market capitalization of $851.36 million, a P/E ratio of -3.38 and a beta of 1.90. The company's 50 day moving average price is $3.64 and its two-hundred day moving average price is $2.70.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. On average, analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.